Hemostatic Disorders
Welcome,         Profile    Billing    Logout  
 195 Companies   327 Products   327 Products   167 Mechanisms of Action   13 Trials   3266 News 


«12...89101112131415161718...6768»
  • ||||||||||  noscapine (CB 3304) / J&J
    Phase classification, Enrollment change, Trial termination:  A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) -  Oct 6, 2016   
    P1,  N=12, Terminated, 
    Active, not recruiting --> Completed Phase classification: P1/2 --> P1 | N=32 --> 12 | Completed --> Terminated; Terminated early due to lack of clinical response.
  • ||||||||||  Trial completion, Trial primary completion date:  EuLITE: European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy (clinicaltrials.gov) -  Oct 5, 2016   
    P=N/A,  N=90, Completed, 
    Phase classification: P1/2 --> P1 | N=32 --> 12 | Completed --> Terminated; Terminated early due to lack of clinical response. Recruiting --> Completed | Trial primary completion date: Jun 2011 --> Jan 2014
  • ||||||||||  alteminostat (CKD-581) / Chong Kun Dang
    Trial completion:  Safety and Pharmacokinetic Profile of CKD-581 (clinicaltrials.gov) -  Oct 5, 2016   
    P1,  N=39, Completed, 
    Recruiting --> Completed | Trial primary completion date: Jun 2011 --> Jan 2014 Recruiting --> Completed
  • ||||||||||  sirexatamab (DKN-01) / Leap Therap
    Trial initiation date, Metastases:  A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors (clinicaltrials.gov) -  Sep 28, 2016   
    P1,  N=32, Completed, 
    Trial primary completion date: Aug 2017 --> Oct 2016 Initiation date: Oct 2011 --> Jan 2012
  • ||||||||||  MRX34 / Synlogic
    Enrollment change, Trial termination:  A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection (clinicaltrials.gov) -  Sep 27, 2016   
    P1,  N=155, Terminated, 
    Active, not recruiting --> Completed N=200 --> 155 | Recruiting --> Terminated; Five immune related serious adverse events
  • ||||||||||  dexamethasone / Generic mfg., bendamustine / Generic mfg., pomalidomide / Generic mfg.
    Clinical:  Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma (clinicaltrials.gov) -  Sep 27, 2016   
    P1/2,  N=56, Active, not recruiting, 
    N=200 --> 155 | Recruiting --> Terminated; Five immune related serious adverse events Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016
  • ||||||||||  bortezomib / Generic mfg.
    Enrollment closed, Enrollment change, Trial primary completion date:  Autophagy Induction After Bortezomib for Myeloma (clinicaltrials.gov) -  Sep 26, 2016   
    P0,  N=11, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Active, not recruiting | N=15 --> 11 | Trial primary completion date: Apr 2016 --> Jun 2015
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Trial completion, Enrollment change, Trial primary completion date:  Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma (clinicaltrials.gov) -  Sep 23, 2016   
    P1/2,  N=11, Completed, 
    Recruiting --> Active, not recruiting | N=15 --> 11 | Trial primary completion date: Apr 2016 --> Jun 2015 Active, not recruiting --> Completed | N=55 --> 11 | Trial primary completion date: May 2017 --> Sep 2016
  • ||||||||||  Enrollment open, Trial initiation date:  MOrPH: Risk Models to Optimise Prophylaxis Schedules in Children With Haemophilia (clinicaltrials.gov) -  Sep 22, 2016   
    P=N/A,  N=20, Enrolling by invitation, 
    Active, not recruiting --> Completed | N=55 --> 11 | Trial primary completion date: May 2017 --> Sep 2016 Not yet recruiting --> Enrolling by invitation | Initiation date: Nov 2015 --> Mar 2016
  • ||||||||||  Enrollment change, Trial primary completion date:  Comprehensive Frailty Assessment (clinicaltrials.gov) -  Sep 22, 2016   
    P=N/A,  N=111, Active, not recruiting, 
    Not yet recruiting --> Enrolling by invitation | Initiation date: Nov 2015 --> Mar 2016 N=400 --> 111 | Trial primary completion date: Nov 2016 --> Jun 2017
  • ||||||||||  melphalan / Generic mfg., clarithromycin / Generic mfg.
    Enrollment change, Trial termination:  CLAIM: Clarithromycin in Multiple Myeloma Induction Therapy (clinicaltrials.gov) -  Sep 20, 2016   
    P2,  N=58, Terminated, 
    Recruiting --> Active, not recruiting N=160 --> 58 | Recruiting --> Terminated; Suspected side effects to the combination of clarithromycin and VCD (bortezomib, cyclophosphamide and dexamethasone)
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi
    Enrollment closed, Enrollment change:  Collection of Transplant Stem Cells for Plasma Cell Myeloma (clinicaltrials.gov) -  Sep 16, 2016   
    P2,  N=49, Active, not recruiting, 
    Active, not recruiting --> Completed | N=36 --> 15 | Trial primary completion date: Aug 2016 --> May 2016 Recruiting --> Active, not recruiting | N=70 --> 49
  • ||||||||||  CYAD-01 / Celdara Medical, Celyad Oncology
    Enrollment closed, Enrollment change, Metastases:  Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands (clinicaltrials.gov) -  Sep 12, 2016   
    P1,  N=12, Active, not recruiting, 
    Trial primary completion date: Mar 2016 --> Sep 2017 Recruiting --> Active, not recruiting | N=21 --> 12
  • ||||||||||  BeneFix (nonacog alfa) / Pfizer
    Trial primary completion date:  BeneFIX Drug Use Results Survey [All-Case Surveillance] (clinicaltrials.gov) -  Sep 9, 2016   
    P=N/A,  N=314, Completed, 
    Recruiting --> Active, not recruiting | N=21 --> 12 Trial primary completion date: May 2014 --> Aug 2014
  • ||||||||||  Xyntha (moroctocog alfa) / Pfizer
    Trial completion:  PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A (clinicaltrials.gov) -  Sep 9, 2016   
    P4,  N=90, Completed, 
    Trial primary completion date: May 2014 --> Aug 2014 Active, not recruiting --> Completed
  • ||||||||||  Clinical data, Trial primary completion date, HEOR:  HAMLET: 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece (clinicaltrials.gov) -  Sep 6, 2016   
    P=N/A,  N=72, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Oct 2016 --> Mar 2017
  • ||||||||||  Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
    Trial completion, Enrollment change:  Interleukin-2 Treatment for Wiskott-Aldrich Syndrome (clinicaltrials.gov) -  Sep 6, 2016   
    P1,  N=9, Completed, 
    Trial primary completion date: Oct 2016 --> Mar 2017 Recruiting --> Completed | N=15 --> 9
  • ||||||||||  cyclophosphamide / Generic mfg., pomalidomide / Generic mfg.
    Combination therapy:  Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide (clinicaltrials.gov) -  Sep 6, 2016   
    P1/2,  N=80, Completed, 
    Recruiting --> Completed | N=15 --> 9 Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Aug 2016